MCID: HML018
MIFTS: 22

Homologous Wasting Disease

Categories: Rare diseases

Aliases & Classifications for Homologous Wasting Disease

MalaCards integrated aliases for Homologous Wasting Disease:

Name: Homologous Wasting Disease 53
Graft-Vs-Host Disease 72

Classifications:



External Ids:

UMLS 72 C0018133

Summaries for Homologous Wasting Disease

MalaCards based summary : Homologous Wasting Disease, is also known as graft-vs-host disease. The drugs Thiotepa and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow.

Related Diseases for Homologous Wasting Disease

Symptoms & Phenotypes for Homologous Wasting Disease

Drugs & Therapeutics for Homologous Wasting Disease

Drugs for Homologous Wasting Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 373, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
5
Promethazine Approved, Investigational Phase 4 60-87-7 4927
6
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
7
Simethicone Approved Phase 4 8050-81-5
8
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
11
Povidone Approved Phase 4 9003-39-8
12
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
15
Semustine Experimental, Investigational Phase 4 13909-09-6
16
Treosulfan Investigational Phase 4 299-75-2 9296
17
Histamine Phosphate Phase 4 51-74-1 65513
18 Antiparasitic Agents Phase 4
19 Antiprotozoal Agents Phase 4
20 Neurotransmitter Agents Phase 4
21 Thymoglobulin Phase 4
22 Anti-Allergic Agents Phase 4
23 Central Nervous System Depressants Phase 4
24 Histamine H1 Antagonists Phase 4
25 Histamine Antagonists Phase 4
26 Hypnotics and Sedatives Phase 4
27 Antipruritics Phase 4
28 Sodium Channel Blockers Phase 4
29 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
30 Antacids Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Plasma Substitutes Phase 4
33 Anti-Arrhythmia Agents Phase 4
34 Viscosupplements Phase 4
35 Emollients Phase 4
36 Anti-Ulcer Agents Phase 4
37 Blood Substitutes Phase 4
38 14-alpha Demethylase Inhibitors Phase 4
39 Steroid Synthesis Inhibitors Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Lubricant Eye Drops Phase 4
42 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
43 Cytochrome P-450 CYP3A Inhibitors Phase 4
44
Hydroxyitraconazole Phase 4
45
Budesonide Approved Phase 3 51333-22-3 63006 5281004
46
Etanercept Approved, Investigational Phase 3 185243-69-0
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
48
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
49
Carmustine Approved, Investigational Phase 2, Phase 3 154-93-8 2578
50
Hydroxychloroquine Approved Phase 3 118-42-3 3652
51
Acyclovir Approved Phase 3 59277-89-3 2022
52
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
53
Idarubicin Approved Phase 3 58957-92-9 42890
54
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
55
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
56
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
57
Pegaspargase Approved, Investigational Phase 3 130167-69-0
58
Atorvastatin Approved Phase 3 134523-00-5 60823
59
Sodium citrate Approved, Investigational Phase 3 68-04-2
60
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
61
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
62
Hydroxyurea Approved Phase 3 127-07-1 3657
63
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 23925 27284
64
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
65
Daunorubicin Approved Phase 3 20830-81-3 30323
66
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
67
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
68
leucovorin Approved Phase 3 58-05-9 143 6006
69
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
70
Etoposide Approved Phase 3 33419-42-0 36462
71
Methoxsalen Approved Phase 3 298-81-7 4114
72
Mesna Approved, Investigational Phase 3 3375-50-6 598
73
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
74
carbamide peroxide Approved Phase 3 124-43-6
75
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
76
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
77
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
78
Serine Approved, Nutraceutical Phase 2, Phase 3 56-45-1 5951
79 Ophthalmic Solutions Phase 3
80 Respiratory System Agents Phase 3
81 Anti-Asthmatic Agents Phase 3
82 Peripheral Nervous System Agents Phase 3
83 Autonomic Agents Phase 3
84 Bronchodilator Agents Phase 3
85 Antiemetics Phase 3
86 BB 1101 Phase 3
87 Analgesics Phase 3
88 Anti-Inflammatory Agents, Non-Steroidal Phase 3
89 Paraproteins Phase 3
90 Myeloma Proteins Phase 3
91 Immunoglobulin Idiotypes Phase 3
92 Antimalarials Phase 3
93 Interferon-gamma Phase 3
94 Tubulin Modulators Phase 3
95 Antimitotic Agents Phase 3
96
asparaginase Phase 3
97 Lipid Regulating Agents Phase 3
98 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
99 Hypolipidemic Agents Phase 3
100 Anticholesteremic Agents Phase 3
101 Antihypertensive Agents Phase 3
102 Adrenergic alpha-2 Receptor Agonists Phase 3
103 Adrenergic alpha-Agonists Phase 3
104 Adrenergic Agonists Phase 3
105 Adrenergic Agents Phase 3
106 Brimonidine Tartrate Phase 3 70359-46-5
107 Acidophilus Phase 3
108 Citrate Phase 3
109 Anticoagulants Phase 3
110 interferons Phase 2, Phase 3
111 Interferon-alpha Phase 2, Phase 3
112 Interferon alpha-2 Phase 2, Phase 3
113 Coagulants Phase 3
114 Gemtuzumab Phase 3
115 Pharmaceutical Solutions Phase 3
116 Antifungal Agents Phase 3
117 Anti-Infective Agents Phase 3
118
Beclomethasone Phase 3 4419-39-0 20469
119 Calcineurin Inhibitors Phase 3
120 Dermatologic Agents Phase 3
121 Folic Acid Antagonists Phase 3
122 Vitamin B9 Phase 3
123 Nucleic Acid Synthesis Inhibitors Phase 3
124 Folate Phase 3
125 Cyclosporins Phase 3
126 Vitamin B Complex Phase 3
127 Protective Agents Phase 3
128 Alpha 1-Antitrypsin Phase 2, Phase 3
129
protease inhibitors Phase 2, Phase 3
130 HIV Protease Inhibitors Phase 2, Phase 3
131 Trypsin Inhibitors Phase 2, Phase 3
132 Serine Proteinase Inhibitors Phase 2, Phase 3
133 Protein C Inhibitor Phase 2, Phase 3
134 Antineoplastic Agents, Phytogenic Phase 3
135 Topoisomerase Inhibitors Phase 3
136 Etoposide phosphate Phase 3
137 Photosensitizing Agents Phase 3
138 Immunoglobulin G Phase 3
139
Bilirubin Phase 3 635-65-4, 69853-43-6 5280352 21252250
140 N-monoacetylcystine Phase 3
141 cysteine Phase 3
142
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
143
Foscarnet Approved Phase 2 63585-09-1, 4428-95-9 3415
144
Furosemide Approved, Vet_approved Phase 1, Phase 2 54-31-9 3440
145
Ustekinumab Approved, Investigational Phase 2 815610-63-0
146
Pomalidomide Approved Phase 2 19171-19-8
147
Maraviroc Approved, Investigational Phase 2 376348-65-1 3002977
148
Granisetron Approved, Investigational Phase 2 109889-09-0 3510
149
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
150
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
151
Azathioprine Approved Phase 2 446-86-6 2265
152
Montelukast Approved Phase 2 158966-92-8 5281040
153
Micafungin Approved, Investigational Phase 2 235114-32-6 3081921 477468
154
Ethanol Approved Phase 2 64-17-5 702
155
Iodine Approved, Investigational Phase 2 7553-56-2 807
156
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
157
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
158
Benzyl alcohol Approved Phase 2 100-51-6 244
159
Phenytoin Approved, Vet_approved Phase 1, Phase 2 57-41-0 1775
160
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
161
Protein C Approved Phase 2
162
Defibrotide Approved, Investigational Phase 2 83712-60-1
163
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
164
tannic acid Approved Phase 2 1401-55-4
165
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
166
Melphalan Approved Phase 2 148-82-3 460612 4053
167
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
168
Natalizumab Approved, Investigational Phase 2 189261-10-7
169
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
170
Pembrolizumab Approved Phase 2 1374853-91-4
171
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
172
Polymyxin B Approved, Vet_approved Phase 2 1404-26-8
173
Vancomycin Approved Phase 2 1404-90-6 441141 14969
174
Ondansetron Approved Phase 2 99614-02-5 4595